GlassScriptPhysician profile
Jordan Ezell Orr
NPI 1184226888
$703.64
in general payments reported to CMS, 2019-2025
14 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2.20 · 2022: $16.25 · 2024: $250 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.57 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $187.54 | 2024-2025 | |
| Boston Scientific Corporation | $52.76 | 2025 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $38.16 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $35.22 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $28.85 | 2024 | Farxiga |
| Exact Sciences Corporation | $28.57 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.66 | 2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.41 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $19.52 | 2024 | Auvelity |
| Genentech USA, INC. | $18.45 | 2021-2022 | |
| Amgen INC. | $14.19 | 2025 | Repatha, Otezla |
| Mylan Specialty L.P. | $14.08 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $13.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.